Byonyks Medical Devices

Byonyks Medical Devices, founded in 2018 and headquartered in San Diego, is a private medical device company developing innovative home-based peritoneal dialysis systems. The company's core achievement is FDA 510(k) clearance for its X-1 APD Cycler, a key milestone that allows it to enter the US market. Byonyks aims to disrupt the stagnant dialysis industry by offering advanced technology designed to improve patient outcomes, preserve kidney function, and lower costs, aligning with a major US government push to shift 80% of dialysis patients to home-based care. The company is led by a team with deep experience in dialysis device development and commercialization.

Next-generation peritoneal dialysis platform focused on biocompatible, toxin-free dialysate, preservation of residual renal function, and cost-effective consumables. Incorporates AI and aims to eliminate pro-inflammatory mediators from treatment.

The APD market is currently served by a small number of large medtech companies, notably Baxter International (with the Homechoice and Amia systems) and Fresenius Medical Care. Byonyks competes by claiming technological superiority in membrane preservation, residual kidney function, and dialysate biocompatibility, aiming to disrupt what it characterizes as a stagnant, 40-year-old technology base.